Imagine a smart, 3D-printed web that acts like a tiny pharmacy implanted in the spine. Instead of a single dose of medicine, this web releases healing agents only when triggered by a wireless signal from outside the body. It focuses on clearing away scar tissue and waking up dormant nerves to help patients regain movement.
Current spinal cord injury treatments fail to promote successful axon regeneration, leaving patients with chronic functional deficits. Existing methods lack the ability to control the timing and dosage of therapeutic agents at the lesion site.
A 3D-bioprinted therapeutic mesh containing three types of nanocarriers that release drugs via wireless electrical triggers.
If you are a device manufacturer dealing with the inability of current implants to deliver drugs precisely—this project developed a 3D-bioprinted mesh that allows for electrically triggered, on-demand release of therapeutic agents.
If you are a biotech firm dealing with the difficulty of delivering gene therapy to the spinal lesion site—this project developed nanocarriers within a mesh that control the time and dose of delivery.
If you are a printing company dealing with the need for functional, bioactive scaffolds—this project developed a 3D-theramesh that integrates organic electronics and nanoparticles for active neural repair.
Based on available project data, there is no information regarding the unit cost or pricing of the theramesh.
The project utilizes 3D bioprinting and includes one industrial partner, but specific industrial scaling metrics are not provided in the current reports.
Based on available project data, the specific patent or licensing terms are not disclosed, though the project is coordinated by CSIC.
The system uses wireless powering to trigger drug release, meaning it can be controlled externally without further invasive surgery.
The project period runs from 2023-01-01 to 2026-12-31, suggesting it is currently in the development and preclinical phase.
The consortium is research-heavy with 7 partners across 6 countries, featuring a strong academic base (2 universities, 3 research centers). While the industry ratio is low at 14% (1 company), the presence of 2 SMEs suggests a focus on translating these 3D-bioprinted prototypes into commercializable medical products.
Contact AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Contact us for a detailed technical deep-dive into the Piezo4Spine nanocarrier specifications.
